Finally, based on the experimental success of synthetic Ffar4 agonist to attenuate metabolic disease (27, 28, 29), we suggest that Ffar4 might be a novel therapeutic target in cardiometabolic disease. This evidence concerns the gene FFAR4 and metabolic disease.